Phaseline

Companies › MicuRx

MicuRx: clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 2 Phase 3, 2 Phase 4; Infectious disease; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Contezolid
Bacterial 70S ribosome inhibitor
DARSPhase 3Diabetic Foot Infection; Mycobacterium Avium Complex Pulmonary Disease; Pulmonary TuberculosisJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06081361ContezolidPhase 3Pulmonary TuberculosisInfectious diseaseDec 2026
NCT05369052ContezolidPhase 3Diabetic Foot InfectionInfectious diseaseJun 2027
NCT07084402ContezolidPhase 4Mycobacterium Avium Complex Pulmonary DiseaseInfectious diseaseJul 2027
NCT07213765ContezolidPhase 4Mycobacterium Avium Complex Pulmonary DiseaseInfectious diseaseSep 2028

Targets

DARS (1)

Companies with the same targets

–

Companies built like this

Laboratorio Farmaceutico SIT srl Zero Point Five Therapeutics Lallemand Pharma Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Jiangxi Qingfeng Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.